Zimmer Biomet becomes first company in the world with 510(k) clearance for Brain, Spine and Knee offerings on one robotic platform
Zimmer Biomet Holdings,. (NYSE and SIX: ZBH), a global in musculoskeletal healthcare, announced U.S. Food and Drug Administration 510(k) clearance of the ROSA® ONE Spine System for robotically assisted minimally invasive and complex spine surgeries, strengthening the Company’s comprehensive ROSA® ONE Brain and ROSA® Knee portfolio.
ROSA ONE Spine combines robotics and navigation while delivering a unique real-time patient ‘dynamic tracking’ capability. The platform features 3D intraoperative planning software in addition to a navigation suite of technologies designed to improve implant as well as instrument placement accuracy and predictability.
“ROSA ONE Spine functions as a dual robotics and navigation technology solution for minimally invasive and complex thoracolumbar spine procedures,” said Aure Bruneau, Zimmer Biomet’s President, Spine, CMF and Thoracic and Surgery Assisting Technology. “We are extremely excited about the addition of ROSA ONE Spine to our already released ROSA ONE Brain and ROSA Knee Systems
Related Reports and Monitors
Apple Watch 4’s PPG and ECG Health Sensors
Reverse Costing - Structural, Process & Cost Report
Nano-Imprint Technology Trends for Semiconductor Applications 2019
Market & Technology